Navigation Links
Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
Date:1/27/2009

- Vimpat(R) demonstrated greater seizure reduction and improved seizure freedom versus placebo when added to first and second-generation antiepileptic drugs (AEDs)

- Phase III study supports recent U.S. FDA and European Commission approvals of Vimpat(R)

ATLANTA, Jan. 27 /PRNewswire-FirstCall/ -- The new antiepileptic drug Vimpat(R) (lacosamide) demonstrated significantly fewer seizures in adult partial-onset epilepsy patients whose seizures were inadequately controlled despite taking up to three other AEDs, according to a Phase III clinical study published online in Epilepsia.

In the study, seizure reduction was measured by:

Primary Endpoints

  • The change in seizure frequency per 28 days from baseline to the maintenance period.
  • The 50 percent responder rate, defined as the proportion of patients experiencing a 50 percent or greater reduction in partial seizure frequency per 28 days from the baseline to the maintenance period.

Secondary Endpoints

  • Seizure freedom:
    • The number and proportion of patients achieving seizure-free status throughout the maintenance period for patients completing the maintenance period.
    • The proportion of seizure-free days during the maintenance period for patients entering the maintenance period.

Vimpat(R) was recently approved by the U.S. Food and Drug Administration (FDA) for use as an add-on therapy for the treatment of partial-onset seizures in adult patients with epilepsy. Earlier this year, the European Commission approved Vimpat(R) for the adjunctive treatment of partial-onset seizures with or without secondary generalization in adult patients with epilepsy.

"These results are particularly encouraging given the number of peopl
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
2. Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinsons Disease
3. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
4. Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
5. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation
8. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
9. Study Shows Machine Perfusion Significantly Improves Transplant Results
10. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
11. New study indicates smallpox vaccination effective for decades
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Wilmington, DE (PRWEB) January 22, 2015 ... the Pistoia Alliance, which helps companies check the legal ... set to expand to China. , As their ... companies are globally adopting software solutions built as a ...
(Date:1/22/2015)... January 22, 2015 Diagenode, Inc., ... as the Bioruptor® and complete solutions for epigenetics ... chromatin immunoprecipitation, alleviating the need for manual processing. ... needed for ChIP of histones or transcription factors ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:1/22/2015)... 22, 2015   GenoSpace , a precision medicine software company ... the broad use of genomic, imaging and other biomedical data ... Michelle Munson , CEO of Aspera, an IBM Company, ... - http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4GenoSpace Expands Board with Appointment of Michelle Munson 2
... in Immunotherapy for ... Alzheimer,s Disease, ... Board: ILNS), a biopharmaceutical company focused on,development of disease-modifying therapeutic ... disorders, announced today,that European Patent No. 1237930 covering chimeric peptide ...
... Sept. 19 Over 20 new speakers will,grace ... Intelligence &,Business Analysis" conference in two weeks in ... pharmaceutical CI, Business Analysis, and Market,Forecasting executives; 200 ... 1-2 to attend the meeting. Competition has never ...
... LAUDERDALE, Fla., Sept. 19 MAKO Surgical,Corp. today announced that ... U.S. Securities and Exchange Commission relating to a proposed,initial public ... shares will be sold by MAKO Surgical Corp. The,number of ... offering have not,yet been determined. The Company intends to apply ...
Cached Biology Technology:Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimer's Vaccine in 19 Countries 2Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimer's Vaccine in 19 Countries 3New Competitive Intelligence Speakers Spark Interest in Pharmaceutical Conference on October 1-2 in NJ 2MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock 2
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season may be ... Market Intelligence reports that the long anticipated floodgates for ... intensifying demand for smart phones, tablets, and wearable mobile ... of 2.5 billion users with nearly 4.8 billion biometric ...
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... they used fluorescent molecules to "tag" DNA and monitor a ... rearranging genetic material in some types of cells. ... light on how DNA loops form, but also might be ... shuffle genetic material, such as HIV. Until now, scientists ...
... more DNA regions linked to type 2 diabetes have been ... to over 60. The study provides a fuller picture ... with some clear patterns emerging. The international team, ... Institute of Harvard and MIT, and the University of Michigan, ...
... affordable and accessible, we need to pay more attention to ... and the fact that we don,t yet understand what ... Hastings Center Report . The authors are current or former ... Most analyses of the ethical issues raised by whole ...
Cached Biology News:Scientists use light to 'tag and track' genetic processes 210 new diabetes gene links offer picture of biology underlying disease 210 new diabetes gene links offer picture of biology underlying disease 3Prenatal whole genome sequencing: Just because we can, should we? 2Prenatal whole genome sequencing: Just because we can, should we? 3
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
...
... Signet offers the most comprehensive, cost-effective ... We have incorporated unprecedented quality into ... This includes proven detection chemistries and ... the TechMate protocol. It also includes ...
Biology Products: